Table 2.

Antiviral activity of FDA-approved compounds in HCV cell culture.

Protein	Compound	In vitro activity (EC50, nM)								Ref.
		GT-1a	GT-1b	GT-2a	GT-2b	GT-3a	GT-4a	GT-5a	GT-6a
NS3/4A	Boceprevir (SCH503034)	196 ± 56	251 ± 71	283 ± 36	315 ± 30	159 ± 5	–	–	–	Silva et al., 2013
	Telaprevir (VX-950)	395 ± 16	285 ± 60	252 ± 54	402 ± 52	953 ± 103	–	–	–	Silva et al., 2013
	Paritaprevir (ABT-450)	1.0 ± 0.33	0.21 ± 0.07	5.3 ± 1.2	–	19 ± 5.2	0.09 ± 0.03	–	0.69 ± 0.09	Pilot-Matias et al., 2015
	Grazoprevir (MK-5172)	0.4 ± 0.2	0.5 ± 0.3	2.3 ± 1.2	3.7 ± 1.1	2.1 ± 1	0.3 ± 0.2	6.6 ± 0.6	0.9 ± 0.1	Lahser et al., 2016
	Simeprevir (TMC435)	28.4 (19–39.7)	8.1 (4.5–11.9)	–	–	–	–	–	–	Lin et al., 2009
NS5A	Daclatasvir (BMS-790052)	0.05 ± 0.013	0.009 ± 0.004	0.071 ± 0.017	–	0.146 ± 0.034	0.012 ± 0.004	0.033 ± 0.01		Gao et al., 2010
	Ledipasvir (GS-5885)	0.031	0.004	21	16	168	0.39	0.15	1.1	Cheng et al., 2016
	Ombitasvir (ABT-267)	0.0141 ± 0.0068	0.005 ± 0.0019	0.0124 ± 0.0027	0.0043 ± 0.0012	0.0193 ± 0.0058	0.00171 ± 0.00088	0.0043 ± 0.0009	0.415 ± 0.097	DeGoey et al., 2014
	Elbasvir (MK-8742)	0.004 ± 0.002	0.003 ± 0.001	0.003 ± 0.001	3.4 ± 2.6	0.14 ± 0.09	0.0003 ± 0.0001	0.001 ± 0.001	0.009 ± 0.006	Lahser et al., 2016
	Velpatasvir (GS-5816)	0.013	0.015	0.009	0.01	0.013	0.009	0.059	0.007	Cheng et al., 2013
NS5B	Sofosbuvir (GS-7977)	44 ± 4.7	48 ± 13	37 ± 3.6	20 ± 4.4	16 ± 3.4	–	–	–	Lam et al., 2012
	Dasabuvir (ABT-333)	7.7 ± 3.8	1.8 ± 0.98	–	–	–	–	–	–	Kati et al., 2015

-: Unavailable data. Information of HCV strains and experimental settings is available in the literature.